Drug Trial Radar · NCT04802733
Phase 1 Safety and Tolerability Study of MSK-DA01 Cell Therapy for Advanced Parkinson's Disease
Last checked: Nov 20, 2026Latest source record: Nov 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12
Actual
Start
May 3, 2021
Primary completion
May 18, 2023
Study completion Jun 10, 2024
Sponsor
- Lead sponsor
- BlueRock TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- Memorial Sloan Kettering Cancer Center
- First posted
- Mar 17, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years, up to 78 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial is designed to test whether surgically injecting nerve cells that make dopamine into the brain of Parkinson's disease patients is safe, and to monitor for potential side effects.
Conditions
- Advanced Parkinson's Disease
Interventions
MSK-DA01Biological
MSK-DA01 is an experimental product derived from human embryonic stem cells. The stem cells were converted into brain cells that produce dopamine.
MSK-DA01 Cell Delivery DeviceDevice
A device that is used for injection of fluids into the brain will be used. Some minor modifications have been made to the device to allow delivery of MSK-DA01 cells.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and TolerabilityTime frame: Baseline to 1 Year Post-Transplant
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
University of California Irvine
Orange, California
Weill Cornell Medical College
New York, New York
Toronto Western Hospital
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.